营养补充剂治疗精神障碍的疗效与安全性:随机对照试验荟萃分析的再评价
该研究对33项安慰剂对照随机对照试验的荟萃分析进行再评价,主要分析涵盖10,951名受试者。最强证据支持多不饱和脂肪酸(尤其是二十碳五烯酸)作为抑郁症的辅助治疗;叶酸类补充剂对重性抑郁障碍的高剂量甲基叶酸有积极效果;N-乙酰半胱氨酸在心境障碍和精神分裂症中有初步证据。所有营养补充剂安全性良好,无严重不良反应或与精神药物禁忌的证据。
要点
- 多不饱和脂肪酸(尤以二十碳五烯酸)辅助治疗抑郁症证据最强。
- 高剂量甲基叶酸对重性抑郁障碍有积极效果。
- 所有营养补充剂安全性良好,无严重不良反应证据。
核心结论
- 临床医生应了解对特定状况有确切疗效的营养补充剂(如二十碳五烯酸用于抑郁症),同时知晓目前缺乏证据支持的补充剂。
研究设计与样本
- 系统检索并再评价33项安慰剂对照随机对照试验的荟萃分析,主要分析纳入10,951名个体的结局数据。
主要发现
- 最强证据支持多不饱和脂肪酸(尤其是二十碳五烯酸)作为抑郁症的辅助治疗。
- 初步证据提示多不饱和脂肪酸可能对注意缺陷/多动障碍有益,但对精神分裂症无证据。
- 叶酸类补充剂被广泛研究作为抑郁症和精神分裂症的辅助治疗,高剂量甲基叶酸在重性抑郁障碍的随机对照试验中显示积极效果。
- N-乙酰半胱氨酸作为心境障碍和精神分裂症的有用辅助治疗有新兴证据。
- 所有营养补充剂安全性良好,无严重不良反应或与精神药物禁忌的证据。
关键数值与推荐
- 共纳入33项安慰剂对照随机对照试验的荟萃分析,主要分析包括10,951名个体的结局数据。
临床怎么用
- 临床医生应知晓二十碳五烯酸对抑郁症有确切疗效,并了解其他营养补充剂证据缺乏的情况。
局限性
- 未来研究应确定哪些个体最可能从循证补充剂中获益,并进一步阐明其潜在机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The role of nutrition in mental health is becoming increasingly acknowledged. Along with dietary intake, nutrition can also be obtained from "nutrient supplements", such as polyunsaturated fatty acids (PUFAs), vitamins, minerals, antioxidants, amino acids and pre/probiotic supplements. Recently, a large number of meta-analyses have emerged examining nutrient supplements in the treatment of mental disorders. To produce a meta-review of this top-tier evidence, we identified, synthesized and appraised all meta-analyses of randomized controlled trials (RCTs) reporting on the efficacy and safety of nutrient supplements in common and severe mental disorders. Our systematic search identified 33 meta-analyses of placebo-controlled RCTs, with primary analyses including outcome data from 10,951 individuals. The strongest evidence was found for PUFAs (particularly as eicosapentaenoic acid) as an adjunctive treatment for depression. More nascent evidence suggested that PUFAs may also be beneficial for attention-deficit/hyperactivity disorder, whereas there was no evidence for schizophrenia. Folate-based supplements were widely researched as adjunctive treatments for depression and schizophrenia, with positive effects from RCTs of high-dose methylfolate in major depressive disorder. There was emergent evidence for N-acetylcysteine as a useful adjunctive treatment in mood disorders and schizophrenia. All nutrient supplements had good safety profiles, with no evidence of serious adverse effects or contraindications with psychiatric medications. In conclusion, clinicians should be informed of the nutrient supplements with established efficacy for certain conditions (such as eicosapentaenoic acid in depression), but also made aware of those currently lacking evidentiary support. Future research should aim to determine which individuals may benefit most from evidence-based supplements, to further elucidate the underlying mechanisms.
引用
- Firth J, Teasdale SB, Allott K, et al. The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry. 2019. PMID: 31496103. doi:10.1002/wps.20672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。